MDxHealth (NASDAQ:MDXH) Announces Quarterly Earnings Results

MDxHealth (NASDAQ:MDXH) issued its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04), Zacks reports. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%.

MDxHealth Stock Down 7.4%

NASDAQ MDXH traded down $0.33 during trading hours on Wednesday, hitting $4.12. The company had a trading volume of 205,471 shares, compared to its average volume of 119,766. The firm’s 50 day moving average is $4.30 and its 200 day moving average is $3.03. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $5.33. The company has a market capitalization of $194.83 million, a price-to-earnings ratio of -4.68 and a beta of 1.68.

Analyst Ratings Changes

Several brokerages have recently issued reports on MDXH. Craig Hallum assumed coverage on shares of MDxHealth in a research note on Thursday, July 17th. They set a “buy” rating and a $8.00 price objective for the company. Wall Street Zen upgraded MDxHealth to a “hold” rating in a research note on Saturday, August 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.